|Videos|August 31, 2021
PI3K inhibitors for R/R CLL
An overview of data for PI3K inhibitors for in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.
The FDA has approved pirtobrutinib for the treatment of adult patients with previously untreated CLL or SLL harboring no known 17p deletion.
The NMPA has approved of pirtobrutinib in treatment-naive and previously treated CLL/SLL.
The top 5 OncLive TV videos of the week cover insights in breast cancer, PV, myeloma, and CLL.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
2
FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer
3
September Roundup of FDA Approvals in Oncology: 8 Decisions to Know
4
VIR-5500 Receives FDA Fast Track Designation in mCRPC
5